Pacira Biosciences Inc at Barclays Global Healthcare Conference Transcript
(technical difficulty) given the fact that we have some opportunities there, frankly, for example, if they're not doing procedures and patients require pain control, then we have other assets in our portfolio that would be positively impacted by that. And so, it's a combination of all of those things that gave us the guidance that we think is appropriately conservative, given everything that's going on in the macro environment.
Questions & Answers
Great. Since the earnings call David, there had done also I think post your commentaries around 340B, especially, in January, I think that's where we've gotten some of the most calls on trying to understand these dynamics of 340B, non-340B, what is the mix? What is the impact? And then, of course, leads into no pain act. So could you maybe take us through that and help us understand this volume growth in the context of this?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
